Bristol/Agios AML’s Idhifa Fails In Phase III, But Approval Seems Secure
Executive Summary
Idhifa is already approved in the US for relapsed or refractory AML patients with IDH2 mutations based on Phase I/II complete responses, but did not meet the overall survival endpoint in the Phase III IDHENTIFY.